Q-omics provides the consensus-scored MYH8 profile across patient tissues and cancer cell-line models. MYH8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MYH8 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, MYH8 protein abundance shows 28,427 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, KICH, and HNSC as cancer lineages where MYH8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYH8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYH8 survival associations across molecular data types. MYH8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYH8 RNA expression–survival associations across cancer types. High MYH8 expression shows unfavorable associations in ACC, HNSC, SCLC and READ, but favorable associations in KIRP and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MYH8 RNA expression.
This table summarizes MYH8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 8. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MYH8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYH8 shows lower tumor expression in KICH, KIRP and KIRC and higher tumor expression in LUAD and LIHC. The KICH box plot shows higher MYH8 RNA expression in normal versus tumor tissue (log2 FC = −2.098, t-test p < 0.001).
This table shows molecular features associated with MYH8 in patient tissues and cancer cell lines. In patient samples, MYH8 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYH8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
